Trevi Therapeutics Q2 2024 GAAP EPS $(0.12) Misses $(0.11) Estimate
Portfolio Pulse from Benzinga Newsdesk
Trevi Therapeutics (NASDAQ:TRVI) reported a Q2 2024 GAAP EPS of $(0.12), missing the analyst consensus estimate of $(0.11) by 9.09%.
August 08, 2024 | 9:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Trevi Therapeutics reported a Q2 2024 GAAP EPS of $(0.12), missing the analyst consensus estimate of $(0.11) by 9.09%. This miss could lead to a short-term negative impact on the stock price as it indicates worse-than-expected financial performance.
The earnings miss, although slight, indicates that the company's financial performance was worse than analysts expected. This could lead to a short-term decline in the stock price as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100